The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 66 (elevated attention) · dilution pressure elevated · listing risk low · governance risk elevated · runway 10.7 mo · strongest signal: Going-concern language (Aug 14, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language, runway 6–12 months) coexists with live selling machinery (offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 33 |
| Aug 14, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-14; 9 prior 424B filings in 12m filing | 28 |
| Aug 12, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-08-12 (accepted 08:30 ET) filing | 23 |
| Aug 5, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-05; 8 prior 424B filings in 12m filing | 28 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $5,097,850 (as of 2025-03-31) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 26 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~10.7 months runway: liquidity $16,563,705 as of 2026-06-30, burn $18,648,808/yr (annualized 272-day YTD operating cash flow [companyfacts]) filing | 23 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $16,563,705 vs current liabilities $58,787,194 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →